Filing Details

Accession Number:
0001209191-18-047110
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-08-16 17:14:54
Reporting Period:
2018-08-15
Accepted Time:
2018-08-16 17:14:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1396814 Pacira Pharmaceuticals Inc. PCRX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1204788 M David Stack C/O Pacira Pharmaceuticals, Inc.
5 Sylvan Way, Suite 300
Parsippany NJ 07054
Ceo And Chairman Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-08-15 610 $5.49 111,264 No 4 M Direct
Common Stock Acquisiton 2018-08-15 13,481 $10.81 124,745 No 4 M Direct
Common Stock Disposition 2018-08-15 21,198 $47.11 103,547 No 4 S Direct
Common Stock Disposition 2018-08-15 11,864 $47.69 91,683 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2018-08-15 610 $0.00 610 $5.49
Common Stock Stock Option (Right to Buy) Disposition 2018-08-15 13,481 $0.00 13,481 $10.81
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2020-12-29 No 4 M Direct
0 2022-06-05 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 18,596 Indirect By Stack Schroon Mohawk FLP
Common Stock 1,208 Indirect By LCK Investment LLC
Footnotes
  1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
  2. Includes 239 shares of common stock acquired under the issuer's employee stock purchase plan in June 2018.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.40 to $47.375, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.40 to $48.00, inclusive.
  5. Mr. Stack is the general partner of Stack Schroon Mohawk FLP. Mr. Stack and his wife are the owners of LCK Investment LLC.
  6. The stock option vested as to 25% of the option shares on December 29, 2011 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months.
  7. The stock option vested as to 25% of the option shares on June 5, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months.